Tumor Agnostic Role of TMB Biomarker Faces Challenges
August 18th 2022
Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.